HOLX - Hologic, Inc.

Hologic, Inc.

250 Campus Drive
Marlborough, MA 01752
United States
508 263 2900
https://www.hologic.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 6,944

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Stephen P. MacMillan	Chairman, CEO & Pres	4.24M	N/A	1964
Ms. Karleen M. Oberton	Chief Financial Officer	1.58M	N/A	1971
Mr. John M. Griffin	Gen. Counsel	1.47M	N/A	1961
Mr. Jan Verstreken	Group Pres of International	1.24M	N/A	1968
Mr. Paul Malenchini	Chief Information Officer	N/A	N/A	N/A
Ryan M. Simon	VP of Investor Relations	N/A	N/A	N/A
Ms. Elisabeth A. Hellmann	Sr. VP of Global HR & Corp. Communications	N/A	N/A	1969
Ms. Monica Aguirre Berthelot	VP & Chief of Staff	N/A	N/A	N/A
Mr. Patrick Brady	Sr. VP of Global Supply Chain, Quality & Regulatory	N/A	N/A	N/A
Mr. Erik Anderson	Division Pres of Breast & Skeletal Health Solutions	N/A	N/A	1982

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Hologic, Inc.’s ISS Governance QualityScore as of May 1, 2023 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.